vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and UNIVERSAL DISPLAY CORP \PA\ (OLED). Click either name above to swap in a different company.
Nutex Health, Inc. is the larger business by last-quarter revenue ($151.7M vs $142.2M, roughly 1.1× UNIVERSAL DISPLAY CORP \PA\). UNIVERSAL DISPLAY CORP \PA\ runs the higher net margin — 25.2% vs 7.8%, a 17.4% gap on every dollar of revenue. On growth, UNIVERSAL DISPLAY CORP \PA\ posted the faster year-over-year revenue change (-14.5% vs -41.1%). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs -5.3%).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
NUTX vs OLED — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $142.2M |
| Net Profit | $11.8M | $35.9M |
| Gross Margin | 30.4% | 74.6% |
| Operating Margin | 20.4% | 30.1% |
| Net Margin | 7.8% | 25.2% |
| Revenue YoY | -41.1% | -14.5% |
| Net Profit YoY | -80.8% | -44.3% |
| EPS (diluted) | $2.34 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $142.2M | ||
| Q4 25 | $151.7M | $172.9M | ||
| Q3 25 | $267.8M | $139.6M | ||
| Q2 25 | $244.0M | $171.8M | ||
| Q1 25 | $211.8M | $166.3M | ||
| Q4 24 | $257.6M | $162.3M | ||
| Q3 24 | $78.8M | $161.6M | ||
| Q2 24 | $76.1M | $158.5M |
| Q1 26 | — | $35.9M | ||
| Q4 25 | $11.8M | $66.3M | ||
| Q3 25 | $55.4M | $44.0M | ||
| Q2 25 | $-17.7M | $67.3M | ||
| Q1 25 | $21.2M | $64.4M | ||
| Q4 24 | $61.6M | $46.0M | ||
| Q3 24 | $-8.8M | $66.9M | ||
| Q2 24 | $-364.0K | $52.3M |
| Q1 26 | — | 74.6% | ||
| Q4 25 | 30.4% | 76.1% | ||
| Q3 25 | 57.8% | 74.6% | ||
| Q2 25 | 51.2% | 77.2% | ||
| Q1 25 | 55.9% | 77.1% | ||
| Q4 24 | 55.0% | 77.0% | ||
| Q3 24 | 27.8% | 77.8% | ||
| Q2 24 | 29.7% | 75.8% |
| Q1 26 | — | 30.1% | ||
| Q4 25 | 20.4% | 38.9% | ||
| Q3 25 | 48.7% | 30.9% | ||
| Q2 25 | 13.8% | 39.9% | ||
| Q1 25 | 38.1% | 41.9% | ||
| Q4 24 | 44.4% | 32.3% | ||
| Q3 24 | 12.3% | 41.5% | ||
| Q2 24 | 7.0% | 35.6% |
| Q1 26 | — | 25.2% | ||
| Q4 25 | 7.8% | 38.4% | ||
| Q3 25 | 20.7% | 31.5% | ||
| Q2 25 | -7.3% | 39.2% | ||
| Q1 25 | 10.0% | 38.8% | ||
| Q4 24 | 23.9% | 28.4% | ||
| Q3 24 | -11.2% | 41.4% | ||
| Q2 24 | -0.5% | 33.0% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $2.34 | $1.40 | ||
| Q3 25 | $7.76 | $0.92 | ||
| Q2 25 | $-2.95 | $1.41 | ||
| Q1 25 | $3.33 | $1.35 | ||
| Q4 24 | $11.56 | $0.96 | ||
| Q3 24 | $-1.72 | $1.40 | ||
| Q2 24 | $-0.07 | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $516.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $329.4M | — |
| Total Assets | $918.5M | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $516.4M | ||
| Q4 25 | $185.6M | $602.4M | ||
| Q3 25 | $166.0M | $603.0M | ||
| Q2 25 | $96.7M | $525.2M | ||
| Q1 25 | $84.7M | $571.3M | ||
| Q4 24 | $40.6M | $492.7M | ||
| Q3 24 | $46.9M | $551.6M | ||
| Q2 24 | $40.8M | $530.5M |
| Q1 26 | — | — | ||
| Q4 25 | $329.4M | $1.8B | ||
| Q3 25 | $317.2M | $1.7B | ||
| Q2 25 | $235.3M | $1.7B | ||
| Q1 25 | $176.9M | $1.7B | ||
| Q4 24 | $132.4M | $1.6B | ||
| Q3 24 | $60.4M | $1.6B | ||
| Q2 24 | $62.7M | $1.5B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $918.5M | $2.0B | ||
| Q3 25 | $964.5M | $1.9B | ||
| Q2 25 | $841.0M | $1.9B | ||
| Q1 25 | $761.9M | $1.9B | ||
| Q4 24 | $655.3M | $1.8B | ||
| Q3 24 | $438.5M | $1.8B | ||
| Q2 24 | $422.4M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | $108.9M |
| Free Cash FlowOCF − Capex | $69.0M | — |
| FCF MarginFCF / Revenue | 45.5% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | 5.95× | 3.03× |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $108.9M | ||
| Q4 25 | $70.4M | $31.1M | ||
| Q3 25 | $99.5M | $97.2M | ||
| Q2 25 | $27.3M | $51.9M | ||
| Q1 25 | $51.0M | $30.6M | ||
| Q4 24 | $54.0K | $34.7M | ||
| Q3 24 | $6.8M | $79.9M | ||
| Q2 24 | $13.3M | $67.0M |
| Q1 26 | — | — | ||
| Q4 25 | $69.0M | $15.1M | ||
| Q3 25 | $99.2M | $84.3M | ||
| Q2 25 | $26.5M | $37.5M | ||
| Q1 25 | $50.9M | $17.5M | ||
| Q4 24 | $-341.0K | $22.0M | ||
| Q3 24 | $6.2M | $66.2M | ||
| Q2 24 | $12.7M | $57.9M |
| Q1 26 | — | — | ||
| Q4 25 | 45.5% | 8.7% | ||
| Q3 25 | 37.0% | 60.4% | ||
| Q2 25 | 10.9% | 21.8% | ||
| Q1 25 | 24.0% | 10.5% | ||
| Q4 24 | -0.1% | 13.6% | ||
| Q3 24 | 7.8% | 41.0% | ||
| Q2 24 | 16.7% | 36.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 9.3% | ||
| Q3 25 | 0.1% | 9.2% | ||
| Q2 25 | 0.3% | 8.4% | ||
| Q1 25 | 0.0% | 7.9% | ||
| Q4 24 | 0.2% | 7.8% | ||
| Q3 24 | 0.8% | 8.4% | ||
| Q2 24 | 0.7% | 5.8% |
| Q1 26 | — | 3.03× | ||
| Q4 25 | 5.95× | 0.47× | ||
| Q3 25 | 1.80× | 2.21× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | 2.40× | 0.47× | ||
| Q4 24 | 0.00× | 0.75× | ||
| Q3 24 | — | 1.19× | ||
| Q2 24 | — | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
OLED
| Material sales | $83.7M | 59% |
| Royalty and license fees | $54.2M | 38% |
| Contract research services | $4.3M | 3% |
